epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2020-19-4-76-83epidemiology-1057Research ArticleПРАКТИЧЕСКИЕ АСПЕКТЫ ЭПИДЕМИОЛОГИИ И ВАКЦИНОПРОФИЛАКТИКИPRACTICAL ASPECTS OF EPIDEMIOLOGY AND VACCINE PREVENTIONОпыт иммунизации ВИЧ-инфицированных детей против пневмококковой инфекции и гриппаExperience in Immunizing HIV-Infected Children against Pneumococcal Infection and InfluenzaНазароваО. И.NazarovaO. I.

Ольга Ивановна Назарова – к. м. н., главный врач

г. Омск, ул. 50 лет Профсоюзов, дом 119, корпус 1. +7 (3812)-649-466

Olga I. Nazarova – Cand. Sci. (Med.), Chief Doctor 

7 (3812)-649-466

aids@mail55.ruАллеЕ. А.AlleE. A.

Алле Елена Александровна – врач-педиатр, врач-инфекционист 

г. Омск, ул. 50 лет Профсоюзов, дом 119, корпус 1. +7 (3812)-649-466

Elena A. Alle – doctor pediatrician, infectious disease specialist

+7 (3812)-649-466

https://orcid.org/0000-0003-0495-3645ПузыреваЛ. В.PuzyrevaL. V.

Лариса Владимировна Пузырева– к. м. н., доцент кафедры инфекционных болезней 

644099, Омск, ул. Ленина, 12. +7 (3812)-53-26-66

Larisa V. Puzyreva – Cand. Sci. (Med.), Associate Professor of Department of Infectious Diseases

12, Lenin str,, Omsk, 644099, +7 (3812)-53-26-66

puzirevalv@mail.ruФурсевичЛ. Н.FursevichL. N.

Людмила Николаевна Фурсевич – заместитель главного врача по лечебным вопросам 

г. Омск, ул. 50 лет Профсоюзов, дом 119, корпус 1. +7 (3812)-649-466

Lyudmila N. Fursevich – Deputy Chief Physician for Medical Issues

+7 (3812)-649-466

aids@mail55.ruАнтиповаТ. В.AntipovaT. V.

Тамара Валерьевна Антипова – врач-инфекционист, заведующая амбулаторно-поликлиническим отделением № 1 

г. Омск, ул. 50 лет Профсоюзов, дом 119, корпус 1. +7 (3812)-649-466; 36-22-33; 643-025

Tamara V. Antipova – infectious disease doctor, Head of the Outpatient Department No. 1

+7 (3812)-649-466

aids@mail55.ruБУЗ Омской области «Центр по профилактике и борьбе со СПИД и инфекционными заболеваниями»РоссияThe center for prevention and fight about AIDS and infectious diseasesRussian FederationФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk state medical university of the Ministry of Health of the Russian FederationRussian Federation2020110920201947683Copyright &#x00A9; Назарова О.И., Алле Е.А., Пузырева Л.В., Фурсевич Л.Н., Антипова Т.В., 20202020Назарова О.И., Алле Е.А., Пузырева Л.В., Фурсевич Л.Н., Антипова Т.В.Nazarova O.I., Alle E.A., Puzyreva L.V., Fursevich L.N., Antipova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1057вакцинацияпрофилактикаВИЧ-инфицированные детипневмококковая вакцинаПКВ13ППВ23противогриппозная вакцинадетиvaccinationpreventionHIV-infected childrenpneumococcal vaccinePCV13PPV23influenza vaccinechildrenReferencesWeiser J. N., Ferreira D. M., Paton J. C. Streptococcus pneumoniae: transmission, colonization and invasion. // Nat Rev Microbiol. 2018. N 16 (6). Р. 355–367. doi:10.1038/s41579-018-0001-8.Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355–367. doi:10.1038/s41579-018-0001-8.Balsells E., Guillot L., Nair H., Kyaw M.H. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. // PLoS One. 2017. N 12(5). Published 2017 May 9. doi:10.1371/journal.pone.0177113.Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and metaanalysis. PLoS One. 2017;12(5). Published 2017 May 9. doi:10.1371/journal.pone.0177113.Drijkoningen J. J., Rohde G. G. Pneumococcal infection in adults: burden of disease. // Clin Microbiol Infect. 2014. N 20 Suppl 5. Р. 45–51. doi:10.1111/1469-0691.12461. Zachariah D., Manga P. HIV and invasive pneumococcal infection. // Int J Cardiol. 2015. N 198. Р. 157–158. doi:10.1016/j.ijcard.2015.06.167.Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20Suppl 5:45–51. doi:10.1111/1469-0691.12461.ПРЕВЕНАР 13: инструкция по применению лекарственного препарата для медицинского применения: Министерство здравоохранения Российской Федерации. 2018. Доступно на: http://petrovax.ru/upload/Prevenar_13_LLD_04.10.16.pdf.Merck.Zachariah D, Manga P. HIV and invasive pneumococcal infection. Int J Cardiol. 2015;198:157–158. doi:10.1016/j.ijcard.2015.06.167.PNEUMOVAX 23 patient product information. – 2016. - Доступно на: https://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_ppi.pdf. [Дата обращения: 10.06.2019].PREVENAR 13: instrukcija po primeneniju lekarstvennogo preparata dlja medicinskogo primenenija: Ministerstvo Zdravoohranenija Rossijskoj Federacii. 2018 (In Russ.). Available at: http://petrovax.ru/upload/Prevenar_13_LLD_04.10.16.pdf. Accessed: 10 Okt. 2019.Merck. PNEUMOVAX 23 patient product information [Internet]. 2016. Available at: https://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_ppi.pdf. Accessed: 10 Okt. 2019.European Medicines Agency. Annex 1: summary of product characteristics (Prevenar 13). 2016. Доступно на: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf.European Medicines Agency. Annex 1: summary of product characteristics (Prevenar 13) [Internet]. 2016. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf.Вакцинопрофилактика пневмококковой инфекции у взрослых. Федеральные клинические рекомендации. М., 2018.Vakcinoprofilaktika pnevmokokkovoj infekcii u vzroslyh. Federal clinical guidelines. Moscow, 2018 (In Russ.).Rubin L. G., Levin M. J., Ljungman P., et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. // Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014. Vol. 58, N 3. P. 309–18. Epub 2014/01/15. 10.1093/cid/cit816.Rubin LG, Levin MJ, Ljungman P, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014;58(3):309–18. Epub 2014/01/15. 10.1093/cid/cit816.Руководство по клинической иммунологии в респираторной медицине. Костинов М. П., Чучалин А. Г., ред. М.: Группа МДВ, 2018.Rukovodstvo po klinicheskoj immunologii v respiratornoj medicine. Ed.: Kostinov MP, Chuchalin AG. Moscow: Gruppa MDV, 2018(In Russ.).Cohen R., Levy C., Bingen E., Koskas M., et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. // Pediatr. Infect. Dis. J. 2012. Vol. 31, N 3. P. 297–301.Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr. Infect. Dis. J. 2012;31(3):297–301.Weinberger D.M., Givon-Lavi N., Shemer-Avni Y., et al. Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. // Emerg. Infect. Dis. 2013. Vol. 19, N 7. P. 1084–1091.Weinberger DM, Givon-Lavi N, Shemer-Avni Y, et al. Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. Emerg. Infect. Dis. 2013;19(7):1084–1091.Diel M., Laurenz M. Impact of pneumococcal conjugate vaccines on pneumonia among children in Germany. ESPID, 2013.Diel M, Laurenz M. Impact of pneumococcal conjugate vaccines on pneumonia among children in Germany. ESPID, 2013.Tagarro A., Benito A., Sanchez A., et al. Bacteremia in Children Observation Program (BACO) Group. Bacteremic pneumonia before and after Withdrawal of 13-valent pneumococcal conjugate vaccine from a public vaccination program in Spain: a case-control study. // J. Pediatr. 2016. Vol. 171. P. 111–115.Tagarro A, Benito A, Sanchez A, et al. Bacteremia in Children Observation Program (BACO) Group. Bacteremic pneumonia before and after Withdrawal of 13-valent pneumococcal conjugate vaccine from a public vaccination program in Spain: a case-control study. J. Pediatr. 2016;171:111–115.Grant L.R., Hammitt L.L., O’Brien S.E., et al. Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage among American Indians. // Pediatr. Infect. Dis. J. 2016. Vol. 35, N 8. P. 907–914.Grant LR, Hammitt LL, O’Brien SE, et al. Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage among American Indians. Pediatr. Infect. Dis. J. 2016;35(8):907–914.Desai A.P., Sharma D., Crispell E.K., et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. // Pediatr. Infect. Dis. J. 2015. Vol. 34, N 11. P. 1168–1174.Desai AP, Sharma D., Crispell E.K., Baughman W, et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr. Infect. Dis. J. 2015;34(11):1168–1174.Ben-Shimol S., Givon-Lavi N., Greenberg D., et al. Pneumococcal nasopharyngeal carriage in children <5years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. // Hum. Vaccin. Immunother. 2016. Vol. 12, N 2. P. 268–276.Ben-Shimol S, Givon-Lavi N, Greenberg D, et al. Pneumococcal nasopharyngeal carriage in children < 5years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. Hum. Vaccin. Immunother. 2016;12(2): 268–276.Steens A., Caugant D.A., Aaberge I.S., et al. Decreased carriage and genetic shifts in the streptococcus pneumoniae population after changing the 7-valent to the 13-valent pneumococcal vaccine in Norway. // Pediatr. Infect. Dis. J. 2015. Vol. 34, N 8. P. 875–883.Steens A, Caugant DA, Aaberge IS, et al. Decreased carriage and genetic shifts in the streptococcus pneumoniae population after changing the 7-valent to the 13-valent pneumococcal vaccine in Norway. Pediatr. Infect. Dis. J. 2015;34(8): 875–883.Джумагазиев А.А., Райский Д.В., Джальмухамедова Э.И. и др. Иммунизация Str. Pneumonia снижает частоту острых отитов у воспитанников дома ребенка (предварительные результаты. // Журнал инфектологии. 2012. Т 4, № 3. С. 76 –79.Dzhumagaziev AA, Raysky DV, Dzhalmukhamedova EI, et al. Immunizacija Str. Pneumonia snizhaet chastotu ostryh otitov u vospitannikov doma rebenka (predvaritel’nye rezul’taty. Journal of Infectology. 2012;4(3):76–79 (In Russ.).Diao W.Q., Shen N., Yu P.X., et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. // Vaccine. 2016. Vol. 34, N 13. P. 1496 –1503. doi:10.1016/j.vaccine.2016.02.023Diao WQ, Shen N, Yu PX, et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016;34(13):1496–1503. doi:10.1016/j.vaccine.2016.02.023.Suzuki M., Dhoubhadel B.G., Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. // Lancet Infect Dis. 2017. Vol. 17, N 3. P. 313-321. doi:10.1016/S1473-3099(17)30049-X.Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–321. doi:10.1016/S1473-3099(17)30049-XБаранов А. А., Намазова-Баранова Л. С., Брико Н. И. и др. Вакцинопрофилактика пневмококковой инфекции у детей. // Педиатрическая фармакология. 2015. Т. 12 (5). С.550–558. doi: 10.15690/pf.v12i5.1457.Baranov AA, Namazova-Baranova LS, Briko NI, et al. Vakcinoprofilaktika pnevmokokkovoj infekcii u detej. Pediatric pharmacology. 2015;12(5):550–558 (In Russ.). doi: 10.15690/pf.v12i5.1457.Белоцерковская Ю. Г., Романовских А. Г., Стырт Е. А. Пневмококковая вакцина у взрослых снижает риск инфекций, вызванных Streptococcus Pneumoniae. // Клиническая медицина. 2016. Т. 094, № 1. С. 61 –66. DOI 10.18821/0023-2149-2016-94-1-61-66.Belotserkovskaya YuG, Romanovsky AG, Styrt EA. Pnevmokokkovaja vakcina u vzroslyh snizhaet risk infekcij, vyzvannyh Streptococcus Pneumoniae. Clinical medicine. 2016;094(1):61–66 (In Russ.). DOI 10.18821/0023-2149-2016-94-1-61-66.Брико Н.И., Фельдблюм И. В., Бикмиева А. В. и др. Вакцинопрофилактика взрослого населения против пневмококковой инфекции. Антибиотики и химиотерапия. 2019. Т. 65, № 1–2. С. 37–43.Briko NI, Feldblum IV, Bikmieva AV, et al. Vakcinoprofilaktika vzroslogo naselenija protiv pnevmokokkovoj infekcii. Antibiotics and chemotherapy. 2019;65(1–2):37–43 (In Russ.).Зайцев А.Е., Курбатова Е.А., Егорова Н.Б. и др. Иммунологические и эпидемиологические аспекты иммуногенности капсульного полисахарида Streptococcus pneumoniae серотипа 3 в составе пневмококковых вакцин. // Журнал микробиологии, эпидемиологии и иммунобиологии. 2020. Т. 97, № 1. С. 72–82. DOI: https://doi.org/10.36233/0372-9311-2020-97-1-72-82.Zaitsev AE, Kurbatova EA, Egorova NB, et al. Immunologicheskie i jepidemiologicheskie aspekty immunogennosti kapsul’nogo polisaharida Streptococcus pneumoniae serotipa 3 v sostave pnevmokokkovyh vakcin. Journal of Microbiology, Epidemiology and Immunobiology. 2020;97(1):72–82 (In Russ.). DOI: https://doi.org/10.36233/0372-9311-2020-97-1-72-82.Lombardi F., Belmonti S., Fabbiani M., et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate Vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: a pilot, prospective controlled study [Internet]. // PLoS One. 2016. Доступно на: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156523. Ссылка активна на 10.06.2019.Lombardi F, Belmonti S, Fabbiani M, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate Vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: a pilot, prospective controlled study [Internet]. PLoS One. 2016. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156523. Accessed: 10 Okt. 2019.Berical A.C., Harris D., Dela Cruz C.S., et al. Pneumococcal Vaccination Strategies. An Update and Perspective. // Ann Am Thorac Soc. 2016. Vol. 13, N 6. P. 933–944. doi:10.1513/AnnalsATS.201511-778FR.Berical AC, Harris D, Dela Cruz CS, et al. Pneumococcal Vaccination Strategies. An Update and Perspective. Ann Am Thorac Soc. 2016;13(6):933–944. doi:10.1513/AnnalsATS.201511-778FR.World Health Organization. Policy brief: updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: HIV treatment, interim guidance. World Health Organization [Internet]. 2018. Доступно на: http://www.who.int/iris/handle/10665/273632. Ссылка активна на 13.06.19 г.World Health Organization. Policy brief: updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: HIV treatment, interim guidance. World Health Organization [Internet]. 2018. Available at: http://www.who.int/iris/handle/10665/273632. Accessed: 13 Okt. 2019.

The authors declare that there are no conflicts of interest present.